United Therapeutics (NASDAQ:UTHR) Director Nilda Mesa Sells 187 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 187 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $481.63, for a total value of $90,064.81. Following the sale, the director owned 5,286 shares of the company’s stock, valued at approximately $2,545,896.18. This represents a 3.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Trading Up 1.8%

Shares of UTHR traded up $8.36 during trading hours on Wednesday, reaching $484.72. The stock had a trading volume of 328,119 shares, compared to its average volume of 579,435. The firm has a 50-day simple moving average of $455.16 and a 200 day simple moving average of $371.12. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $492.62. The company has a market capitalization of $20.87 billion, a price-to-earnings ratio of 18.37, a P/E/G ratio of 4.76 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same quarter in the previous year, the business posted $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on UTHR. Wells Fargo & Company upped their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Royal Bank Of Canada upped their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Finally, Bank of America lifted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $505.00.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its holdings in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. increased its position in United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in shares of United Therapeutics in the third quarter valued at $317,617,000. Assetmark Inc. lifted its position in shares of United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock valued at $192,571,000 after buying an additional 4,145 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.